Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Financial Year ended 31 March 2026.
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Tatva Chintan Pharma Chem Ltd published extracts of its Q4 and FY2025-26 financial results in Financial Express (English) and Vadodara Samachar (Gujarati) on 17 May 2026. For the full year, net revenue stood at approximately ₹1,554 million (consistent across periods), with EBITDA of around ₹1,250 million. Q4 PAT declined sharply to ₹67 million from ₹255 million in Q4 FY25 — a fall of approximately 73-74% year-over-year. The company operates in specialty chemicals with exports contributing roughly 40% of sales (Europe and America each around 6%, with rest unallocated). The company had previously announced a ₹1,327 crore investment in a new manufacturing facility and launched 32 new products. The filing is pursuant to SEBI LODR Regulations 30 and 47.
The sharp drop in Q4 profit (down ~73-74% YoY) is a significant concern for shareholders. The full-year revenue also shows contraction compared to the prior year, indicating ongoing pressure on margins or demand. Investors should await the full standalone and consolidated results filing for complete context.